Relationship of Zolpidem and Cancer Risk: A Taiwanese Population-Based Cohort Study
Mayo Clinic Proceedings, ISSN: 0025-6196, Vol: 87, Issue: 5, Page: 430-436
2012
- 56Citations
- 63Captures
- 4Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations56
- Citation Indexes55
- 55
- CrossRef51
- Policy Citations1
- Policy Citation1
- Captures63
- Readers63
- 62
- Mentions4
- News Mentions2
- News2
- Blog Mentions1
- Blog1
- References1
- Wikipedia1
Most Recent News
Ending the Vicious Cycle of Insomnia Without Prescription Sleeping Pills
“O sleep! O gentle sleep! Nature’s soft nurse, how have I frighted thee? That thou no more wilt weigh mine eyelids down and sleep my
Article Description
To evaluate the relationship between the use of zolpidem and subsequent cancer risk in Taiwanese patients. We used data from the National Health Insurance system of Taiwan to investigate whether use of zolpidem was related to cancer risk. For the study cohort, we identified 14,950 patients who had received a first prescription for zolpidem from January 1, 1998, through December 31, 2000. For each zolpidem user, we selected randomly 4 comparison patients without a history of using zolpidem who were frequency-matched by sex, age, and year of the index date. Incidence rates of all cancers and selected site-specific cancers were measured by the end of 2009, and related hazard ratios (HRs) and 95% confidence intervals (CIs) of the cancer were measured as well. The risk of developing any cancer was greater in patients using zolpidem than in nonusers (HR, 1.68; 95% CI, 1.55-1.82). The stratified analysis showed that the overall HR for high-dosage zolpidem (≥300 mg/y) was 2.38. The site-specific cancer risk was the highest for oral cancer (HR, 2.36; 95% CI, 1.57-3.56), followed by kidney cancer, esophageal cancer, breast cancer, liver cancer, lung cancer, and bladder cancer (HR, 1.60; 95% CI, 1.06-2.41). Men were at higher risk than women. This population-based study revealed some unexpected findings, suggesting that the use of zolpidem may be associated with an increased risk of subsequent cancer. Further large-scale and in-depth investigations in this area are warranted.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0025619612003059; http://dx.doi.org/10.1016/j.mayocp.2012.02.012; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84860677764&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/22560522; https://linkinghub.elsevier.com/retrieve/pii/S0025619612003059; http://www.mayoclinicproceedings.org/article/S0025-6196(12)00305-9/abstract
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know